Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST - Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other research firms have also issued reports on AQST. Raymond James Financial set a $7.00 target price on Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital dropped their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Oppenheimer assumed coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $7.00 target price for the company. Finally, Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded down $0.01 during trading hours on Tuesday, hitting $3.35. The stock had a trading volume of 798,826 shares, compared to its average volume of 1,548,087. The stock's fifty day simple moving average is $2.80 and its 200 day simple moving average is $3.06. The firm has a market capitalization of $332.26 million, a price-to-earnings ratio of -5.69 and a beta of 1.94. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million for the quarter, compared to the consensus estimate of $12.23 million. As a group, research analysts anticipate that Aquestive Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Aquestive Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Deutsche Bank AG grew its position in shares of Aquestive Therapeutics by 63.9% in the 4th quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock valued at $221,000 after purchasing an additional 24,170 shares during the period. Raymond James Financial Inc. acquired a new position in Aquestive Therapeutics during the fourth quarter worth $498,000. Two Sigma Investments LP raised its holdings in shares of Aquestive Therapeutics by 31.5% in the 4th quarter. Two Sigma Investments LP now owns 175,952 shares of the company's stock valued at $626,000 after purchasing an additional 42,160 shares during the period. ProShare Advisors LLC boosted its stake in shares of Aquestive Therapeutics by 79.8% during the 4th quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock worth $90,000 after acquiring an additional 11,200 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock valued at $15,474,000 after purchasing an additional 82,958 shares during the period. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.